1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 9, 03/Mar/2022
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

To control epidemic waves, it is important to know the susceptibility to SARS-CoV-2 and its evolution over time in relation to the control measures taken.

Aim

To assess the evolving SARS-CoV-2 seroprevalence and seroincidence related to the first national lockdown in Belgium, we performed a nationwide seroprevalence study, stratified by age, sex and region using 3,000–4,000 residual samples during seven periods between 30 March and 17 October 2020.

Methods

We analysed residual sera from ambulatory patients for IgG antibodies against the SARS-CoV-2 S1 protein with a semiquantitative commercial ELISA. Weighted seroprevalence (overall and by age category and sex) and seroincidence during seven consecutive periods were estimated for the Belgian population while accommodating test-specific sensitivity and specificity.

Results

The weighted overall seroprevalence initially increased from 1.8% (95% credible interval (CrI): 1.0–2.6) to 5.3% (95% CrI: 4.2–6.4), implying a seroincidence of 3.4% (95% CrI: 2.4–4.6) between the first and second collection period over a period of 3 weeks during lockdown (start lockdown mid-March 2020). Thereafter, seroprevalence stabilised, however, significant decreases were observed when comparing the third with the fifth, sixth and seventh period, resulting in negative seroincidence estimates after lockdown was lifted. We estimated for the last collection period mid-October 2020 a weighted overall seroprevalence of 4.2% (95% CrI: 3.1–5.2).

Conclusion

During lockdown, an initially small but increasing fraction of the Belgian population showed serologically detectable signs of exposure to SARS-CoV-2, which did not further increase when confinement measures eased and full lockdown was lifted.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.9.2100419
2022-03-03
2024-12-26
/content/10.2807/1560-7917.ES.2022.27.9.2100419
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/9/eurosurv-27-9-3.html?itemId=/content/10.2807/1560-7917.ES.2022.27.9.2100419&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. Geneva: WHO. [Accessed: 26 Aug 2021]. Available from: https://covid19.who.int
  2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.  https://doi.org/10.1038/s41586-020-2012-7  PMID: 32015507 
  3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.  https://doi.org/10.1016/S0140-6736(20)30566-3  PMID: 32171076 
  4. Federale overheidsdienst (FOD). Eén gerepatrieerde landgenoot testte positief op het nieuwe coronavirus. [A repatriated citizen tested positive for the new coronavirus]. Bruxelles: FOD; 2020. Dutch. Available from: https://www.info-coronavirus.be/nl/news/archive/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus/
  5. Federal Planning Bureau (FPB). Population projections 2020-2070. Bruxelles: FPB. [Accessed: 22 Apr 2020]. Available from: https://www.plan.be/databases/data-35-en-population+forecasts+2019+2070
  6. Sciensano. COVID-19 – epidemiologische situatie. Bruxelles: Sciensano. [Accessed: 1 Mar 2021]. Dutch. Available from: https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie
  7. Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, VAN Damme P. Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation. Epidemiol Infect. 2014;142(2):251-61.  https://doi.org/10.1017/S0950268813001064  PMID: 23689103 
  8. Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020.04.09.20056325. preprint.  https://doi.org/10.1101/2020.04.09.20056325 . https://doi.org/10.1101/2020.04.09.20056325 
  9. Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020;26(10):1386-94.  https://doi.org/10.1016/j.cmi.2020.06.024  PMID: 32603801 
  10. EUROIMMUN A. Application of EUROIMMUN tests for COVID-19 diagnostics. Luebeck; EUROIMMUN; 2021. Available from: www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf
  11. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org
  12. Stan Development Team. RStan: the R interface to Stan. R package version 2.21.2. 2020. Available from: https://cran.r-project.org
  13. Stan Development Team. Stan modeling language users guide and reference manual, version 2.18. 2020. Available from: https://mc-stan.org
  14. Lumley T. survey: analysis of complex survey samples. R package version 4.0. 2020. Available from: https://cran.r-project.org
  15. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9.  https://doi.org/10.1016/S0140-6736(20)31304-0  PMID: 32534626 
  16. Borremans B, Gamble A, Prager KC, Helman SK, McClain AM, Cox C, et al. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. eLife. 2020;9:e60122.  https://doi.org/10.7554/eLife.60122  PMID: 32894217 
  17. van der Heide V. Neutralizing antibody response in mild COVID-19. Nat Rev Immunol. 2020;20(6):352.  https://doi.org/10.1038/s41577-020-0325-2  PMID: 32346091 
  18. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.  https://doi.org/10.1038/s41591-020-0965-6  PMID: 32555424 
  19. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598-607.  https://doi.org/10.1038/s41564-020-00813-8  PMID: 33106674 
  20. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020;383(11):1085-7.  https://doi.org/10.1056/NEJMc2025179  PMID: 32706954 
  21. Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21(4):245-56.  https://doi.org/10.1038/s41577-021-00522-1  PMID: 33723416 
  22. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52):eabe0367.  https://doi.org/10.1126/sciimmunol.abe0367  PMID: 33033172 
  23. Sciensano. Aantal bloeddonoren en gezondheidswerkers met antistoffen tegen coronavirus blijft stabiel. [Number of blood donors and health professionals with coronavirus antibodies remains stable]. Bruxelles: Sciensano; 2020. Available from: https://www.sciensano.be/nl/pershoek/aantal-bloeddonoren-en-gezondheidswerkers-met-antistoffen-tegen-coronavirus-blijft-stabiel
  24. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-44.  https://doi.org/10.1016/S0140-6736(20)31483-5  PMID: 32645347 
  25. Public Health England (PHE). Weekly coronavirus disease 2019 (COVID-19) surveillance report. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897481/Weekly_COVID19_Surveillance_Report_w26_UPDATED.pdf
  26. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis. 2021;21(4):e75-6.  https://doi.org/10.1016/S1473-3099(20)30631-9  PMID: 32763195 
Seroprevalence of IgG antibodies against SARS-CoV-2 – a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Sereina+Annik+Herzog&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Herzog Sereina Annik</a>, <a href="/search?value1=Jessie+De+Bie&option1=author&noRedirect=true" class="nonDisambigAuthorLink">De Bie Jessie</a>, <a href="/search?value1=Steven+Abrams&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Abrams Steven</a>, <a href="/search?value1=Ine+Wouters&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wouters Ine</a>, <a href="/search?value1=Esra+Ekinci&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ekinci Esra</a>, <a href="/search?value1=Lisbeth+Patteet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Patteet Lisbeth</a>, <a href="/search?value1=Astrid+Coppens&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Coppens Astrid</a>, <a href="/search?value1=Sandy+De+Spiegeleer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">De Spiegeleer Sandy</a>, <a href="/search?value1=Philippe+Beutels&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Beutels Philippe</a>, <a href="/search?value1=Pierre+Van+Damme&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Van Damme Pierre</a>, <a href="/search?value1=Niel+Hens&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hens Niel</a>, <a href="/search?value1=Heidi+Theeten&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Theeten Heidi</a></span>. Seroprevalence of IgG antibodies against SARS-CoV-2 – a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(9):pii=2100419. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.9.2100419" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.9.2100419</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 07 Apr 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 10 Sept 2021 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.9.2100419
/content/10.2807/1560-7917.ES.2022.27.9.2100419
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error